Carin A. Uyl-de Groot is Professor of Health Technology Assessment at the Erasmus University Rotterdam, the Netherlands. Since 2000, she is director of the institute for Medical Technology Assessment (iMTA b.v.). From 2012-2022, she was head of the department ‘Health Technology Assessment (HTA)’ of the Erasmus School of Health Policy & Management. She has been program leader of cancer studies at the iMTA since 1994. She was chair of the Dutch Foundation of Technology Assessment in Health Care from 2011-2016. In 2014 she has been co-chair of the 17th European Congress of the International Society for PharmacoEconomic Outcomes Research (ISPOR) in Amsterdam. In 2018, she was chair to the public health and health economics track of the European Society of Medical Oncology (ESMO) conference in Munich.

Furthermore, she served as a member of the Dutch Committee on Expensive Cancer Drugs (CieBOM). Since September 2015 she has been a member of the Dutch Health Council. Her research activities are mainly focused on cost-effectiveness and outcomes studies particularly in the cancer field. Her main interests consist of diagnostic and therapeutic technologies, economic studies linked to clinical studies, modeling studies, cost studies, quality of life studies, methodological issues and implementation studies. She has also been involved in the development of clinical practice guidelines. She is principal investigator of several cancer registries and outcomes studies.

Maureen Rutten-van Mölken is Professor of Economic Evaluation of Innovations for Health at the Erasmus School of Health Policy & Management, Erasmus University Rotterdam. She is head of the department ‘Health Technology Assessment’ (HTA) and also scientific Director of the Institute for Medical Technology Assessment (IMTA). She teaches “Health Technology Assessment” and “Pharmaceutical Pricing and Market Access” in the Master-program Health Economics Policy and Law at Erasmus University Rotterdam. Her expertise includes economic evaluation studies, either alongside clinical trials or using probabilistic decision-analytic modeling, and outcomes research. She has a special interest in the cost-effectiveness and the financing and payment of complex multi-faceted interventions that involve system-level changes like integrated care programs, disease management programs, hospital at home programs, outpatient rehabilitation programs, etc. She also has an interest in the health economics of personalized medicine.

She has almost 30 years of experience and has been leading many applied economic evaluations and HTA methods-studies leading to high-level publications. She is the coordinator of SELFIE, a Horizon2020 project on integrated care in multi-morbidity.

Nicolas Xander is a PhD candidate at the department of Health Technology Assessment at the Erasmus School of Health Policy & Management, Erasmus University Rotterdam. Originally, he has a background in law (diploma 2012, doctorate 2018), and acquired working experience in various law offices in Liechtenstein as well as in the Liechtenstein state administration. He obtained a master’s degree in Health Economics, Policy & Law at Erasmus University in 2022. His research concerns the pricing, economic evaluation, and reimbursement decision-making of anti-cancer treatments.

Marcel Langone Marques is Project Manager at Erasmus University Rotterdam. Over the past 6 years, he has worked in Project Management and Event Management in private and public organizations at an European and Global level. Initially managing renewable energy projects, Marcel has expanded its project management scope and action in healthcare and migration.

Tom Belleman is a PhD candidate at the Health Technology Assessment department of the Erasmus School of Health Policy & Management, Erasmus University Rotterdam. He graduated from the Vrije Universiteit Amsterdam with a Bachelor’s degree in Biomedical Sciences in 2020. After this, he completed a master’s degree in Health Economics, Policy & Law (2022) at the Erasmus University. His research concerns pricing, cost-effectiveness, and reimbursement for cancer treatments.